Compare FirstEnergy Corp. (FE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Sanofi SA — how do they compare? FirstEnergy Corp. trades at $46.86 (market cap $27.06B), while Sanofi SA trades at $43.6 (market cap $104.57B). The key difference: Sanofi SA is far larger — about 3.9× FirstEnergy Corp.'s market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.
| FE | SNY | |
|---|---|---|
Market Cap | $27.06B | $104.57B |
Sector | Utilities | Health |
52-Week High | $51.91 | $52.34 |
52-Week Low | $42.83 | $41.33 |
Enterprise Value | $55.98B | $124.48B |
Dividend Yield | 3.98% | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $47.47, up 0.2% today, with a bearish technical signal from indicators like the 6-day RSI at 11.10 and ADX signaling strong trend strength. The company reported Q2 2026 EPS of $0.50, slightly missing expectations, but revenue growth is supported by data center demand and a $36 billion grid investment plan. Analyst consensus is a Buy with a $52.67 price target, though technicals suggest near-term pressure.
The outlook is mixed: strong fundamentals with rising revenue and stable margins offer long-term value, but technical bearishness and high debt levels pose risks. Investment opportunity lies in grid expansion and data center growth, while risks include execution challenges and interest rate sensitivity. The stock presents a defensive play with growth potential amid volatility.
SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.
SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
